Abstract
BackgroundPatients with pathologic stage (p-Stage) IA non-small cell lung cancer (NSCLC) have a good survival rate because of possible curative resection. However, up to 10% of these patients relapse postoperatively. To identify unfavorable prognostic factors, we retrospectively analyzed the clinicopathological features of p-Stage IA disease, focusing on vascular invasion.MethodsOf 467 patients with p-Stage I NSCLC, 335 were diagnosed with p-Stage IA or IB disease based on a lesion size ≤3 cm and the presence of pleural invasion (PL). Univariate and multivariate analyses of recurrence-free survival (RFS) were performed with age, sex, PL, and vascular invasion (blood vessel invasion [v] and lymphatic vessel invasion [ly]) as variables. To examine vascular invasion, hematoxylin-eosin (HE), Elastica van Gieson staining, and immunostaining with anti-podoplanin antibody were performed. The presence or absence of v and ly was recorded; the number of involved vessels was counted. Survival rates were obtained using the Kaplan–Meier method and log-rank test. Multivariate analyses were performed using the Cox proportional hazards model.ResultsRFS differed significantly between patients with no or one involved blood vessel (0 v or 1 v) and those with ≥2 involved vessels (≥2 v). Similarly, RFS differed significantly between patients with no lymphatic vessel involvement (0 ly) and those with one involved lymphatic vessel (1 ly). Thus, BVI(+) and BVI(−) were defined as ≥2 v and 0 v + 1 v, and LVI(+) and LVI(−) as ≥1 ly and 0 ly, respectively. BVI and LVI together represented tumor vessel invasion (TVI). On multivariate analyses, PL and TVI were independently associated with recurrence. Additionally, patients with p-Stage IA TVI(+) disease had a comparable recurrence rate to those with p-Stage IB disease.ConclusionsSimilar to PL, TVI is an important factor increasing the likelihood of recurrence. As HE staining alone is insufficient for evaluating vascular invasion, specific staining is necessary. Moreover, patients with p-Stage IA TVI(+) disease had a recurrence rate comparable to those with p-Stage IB disease; therefore, further studies should aim to elucidate whether patients with p-Stage IA TVI(+) disease should be administered postoperative chemotherapy similar to that received by p-Stage IB patients.Virtual SlidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5213064891369688
Highlights
Patients with pathologic stage (p-Stage) IA non-small cell lung cancer (NSCLC) have a good survival rate because of possible curative resection
Postoperative chemotherapy is currently administered to patients with pathological stage (p-Stage) IB cancer, as the efficacy of postoperative adjuvant chemotherapy in these patients has been proven in several global studies [1,2,3], and postoperative oral tegafur-uracil has proved efficacious in a group of Japanese patients [4,5]
We investigated whether v and ly are independent prognostic factors for recurrence in patients with p-Stage I NSCLC by comparing them with other factors, and examined whether differences in recurrence rates according to vascular invasion are useful in reconsidering the application of additional postoperative treatment
Summary
Patients with pathologic stage (p-Stage) IA non-small cell lung cancer (NSCLC) have a good survival rate because of possible curative resection. Postoperative chemotherapy is currently administered to patients with pathological stage (p-Stage) IB cancer, as the efficacy of postoperative adjuvant chemotherapy in these patients has been proven in several global studies [1,2,3], and postoperative oral tegafur-uracil has proved efficacious in a group of Japanese patients [4,5]. Patients with p-Stage IA cancer often only receive follow-up care after surgery because their outcome is generally favorable without postoperative chemotherapy. Chemotherapy including tegafur-uracil is not currently administered to patients with p-Stage IA disease, because of the observed adverse effects. In the 7th edition of the Union for International Cancer Control TNM Classification, published in 2009, PL was reappraised as a pathological factor that distinguishes p-Stage IA from p-Stage IB disease. Travis et al [12,13] recommended the use of elastic fiber staining to improve the accuracy of its determination
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.